Announcements
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
- Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
- Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
- Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
- Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
More ▼
Key statistics
On Thursday, Axsome Therapeutics Inc (19X:DUS) closed at 73.44, -18.92% below its 52-week high of 90.58, set on Feb 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 71.58 |
---|---|
High | 73.44 |
Low | 71.58 |
Bid | -- |
Offer | -- |
Previous close | 72.64 |
Average volume | 91.40 |
---|---|
Shares outstanding | 47.37m |
Free float | 38.22m |
P/E (TTM) | -- |
Market cap | 3.78bn USD |
EPS (TTM) | -5.20 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 18:30 BST.
More ▼